RxDoctor Payments Data

Seth Tuwiner, MD

Neurology · Leesburg, VANPI 1942497235

Payments from drug & device makers

$3,405in general payments, 2019–2025

Across 322 payments — averaging $10.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$880
  • Amneal Pharmaceuticals LLC$391
  • Integra Lifesciences Corporation$166
  • Argenx US, Inc.$159
  • Biohaven Pharmaceuticals, Inc.$154
  • plus $518 from 15 others

What the payments were for

  • Speaking & faculty fees$211%
  • Food & beverage$3,38499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,405 in reported general payments places this provider in the 60th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$58,830
Medicare patients
263
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate13$63,636
RytaryCarbidopa/Levodopa18$30,563
QuliptaAtogepant14$27,088
EliquisApixaban11$10,515
Lacosamide40$9,131
Ajovy AutoinjectorFremanezumab-Vfrm13$8,603
Depakote ErDivalproex Sodium12$8,377
Aimovig AutoinjectorErenumab-Aooe11$7,719
TrileptalOxcarbazepine12$7,099
Carbidopa-LevodopaCarbidopa/Levodopa77$2,336
Levetiracetam49$1,782
Duloxetine Hcl21$1,584
Gabapentin81$1,053
Pregabalin36$1,026
Donepezil Hcl79$781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$391$30,56318 claims
AbbVieQulipta$880$27,08814 claims
PfizerEliquis$85$10,51511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 474 neurology providers in Virginia.

Other neurology in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →